0001437749-23-007443.txt : 20230321
0001437749-23-007443.hdr.sgml : 20230321
20230321200642
ACCESSION NUMBER: 0001437749-23-007443
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230317
FILED AS OF DATE: 20230321
DATE AS OF CHANGE: 20230321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Floroiu Cezar Andrei
CENTRAL INDEX KEY: 0001808794
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35285
FILM NUMBER: 23751038
MAIL ADDRESS:
STREET 1: C/O VAXART, INC.
STREET 2: 385 OYSTER POINT BOULEVARD, SUITE 9A
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxart, Inc.
CENTRAL INDEX KEY: 0000072444
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 591212264
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 HARBOR WAY, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 550-3500
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Aviragen Therapeutics, Inc.
DATE OF NAME CHANGE: 20160413
FORMER COMPANY:
FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20121113
FORMER COMPANY:
FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS
DATE OF NAME CHANGE: 20100719
4
1
rdgdoc.xml
FORM 4
X0407
4
2023-03-17
0000072444
Vaxart, Inc.
VXRT
0001808794
Floroiu Cezar Andrei
C/O VAXART, INC.
170 HARBOR WAY, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
1
President, Chief Exec Officer
0
Common Stock
2023-03-17
4
A
0
100000
0
A
185000
D
Common Stock
2023-03-17
4
A
0
92735
0
A
277735
D
Common Stock
2023-03-17
4
A
0
175000
0
A
452735
D
Stock Option (right to buy)
0.78
2023-03-17
4
A
0
400000
0
A
2033-03-16
Common Stock
400000
400000
D
Stock Option (right to buy)
0.78
2023-03-17
4
A
0
750000
0
A
2033-03-16
Common Stock
750000
750000
D
Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023.
The shares subject to this stock option shall fully vest on December 8, 2023.
Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date.
The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027.
/s/ Andrei Floroiu
2023-03-21